PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia. james.mcmahon@monash.edu.\', \'Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia. james.mcmahon@monash.edu.\', \'Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.\', \'Department of Infectious Diseases, Eastern Health, Melbourne, Australia.\', \'Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.\', \'Department of Infectious Diseases, Austin Hospital, Melbourne, Australia.\', \'Department of Infectious Diseases, Royal Melbourne Hospital, Melbourne, Australia.\', \'Department of Infectious Diseases, Western Health, Melbourne, Australia.\', \'Epworth Healthcare, Melbourne, Australia.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-020-04766-5
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 33050947
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
?:title
  • An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all